Related Experiment Video
Updated: Jan 20, 2026
05:18
Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome
Published on: May 26, 2023
1.8K
Office-based corticosteroid injections as adjuvant therapy for subglottic stenosis
1Department of Otolaryngology University of Miami Miller School of Medicine Miami Florida U.S.A.
Laryngoscope Investigative Otolaryngology
|August 28, 2019
Summary
Subglottic stenosis (SGS) treatment improved with corticosteroid injections. Office-based steroid injections significantly increased surgery-free intervals (SFIs) in SGS patients, offering a promising adjuvant therapy.
Area of Science:
- Otolaryngology
- Pulmonology
- Medical Innovation
Background:
- Subglottic stenosis (SGS) presents significant treatment challenges due to high recurrence rates.
- Conventional management relies on serial endoscopic dilation, often with limited long-term success.
Purpose of the Study:
- To evaluate the efficacy of subglottic corticosteroid injections as an adjuvant therapy for SGS.
- To determine if these injections can increase surgery-free intervals (SFIs) in patients with SGS.
Main Methods:
- Retrospective chart review of SGS patients undergoing endoscopic dilation and office-based steroid injections (SILSI).
- Calculation and comparison of SFIs before and after SILSI initiation.
- Statistical analysis using Mann-Whitney U test to assess significance (P < .05).
Main Results:
- Thirteen patients (mean age 50.1 years; 7:6 female:male) were included.
- The mean SFI significantly increased from 288.6 days before SILSI to 545.5 days after SILSI (P = .0041).
- Intubation-related stenosis was the most common cause (61.5%).
Conclusions:
- Office-based corticosteroid injections are associated with a statistically significant improvement in SFIs for SGS.
- SILSI represents a promising adjuvant treatment approach for managing subglottic stenosis.
- Further prospective studies are warranted to confirm efficacy and guide integration into standard care.
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
746
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
746
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
1.5K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.5K
01:22Mitral Stenosis I: Introduction
504
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
504
00:59Gene Therapy
27.4K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.4K
01:26Mitral Stenosis III: Medical Management
251
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
251
01:27Mitral Stenosis IV: Nursing Management
249
A comprehensive nursing assessment is essential for patients with valvular heart disease, which involves any dysfunction of the heart valves that could impact blood flow and overall heart function.Subjective Data Collection:Chief Complaint and Present Illness: Start with the patient's primary concerns, focusing on the onset, duration, and progression of cardiac symptoms such as dyspnea, fatigue, chest pain, and palpitations.Past Medical History: Collect detailed information on any previous...
249